

June 1, 2012

Dear Valued Customer.

This letter is to inform you of an important update regarding CHROMITOPE® Sodium (Sodium Chromate Cr 51 Injection USP).

CHROMITOPE will be available only through July 15, 2012, which will be the final selling date. Once the current residual stock is depleted, the product will no longer be available from Bracco Diagnostics Inc. CHROMITOPE will be discontinued, effective July 15, 2012.

Bracco is committed to our customers and the patients we serve. However, owing to the significant decline over the last several years in medical examinations requiring CHROMITOPE, and the recent discontinuation of Bracco A-C-D Solution ModifiedTM, which is the complementary product for the performance of those examinations, we can no longer offer CHROMITOPE to the healthcare community.

Product Name/ Description	Clinical Use Description	Additional Commentary
No. of the last of	DELIGHT STATE STATE OF THE STAT	
Chromitope Sodium 1.00 mCi	Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in	There are no substitution products available
eg e se erembiguati		
sinecación, adoptional	evaluating blood loss.	inforced from the
	Description Chromitope Sodium 1.00 mCi	Chromitope Sodium 1.00 mCi Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and

If you have any questions or require additional assistance, please contact us. Thank you for your ongoing support of Bracco and our clinically valued products.

Regards

Kim Giordano

Vice President and General Manager

Nuclear Medicine (609)514-2333

Bracco Diagnostics Inc.

107 College Road East - Princeton, NJ 08540 USA Telephone: (609) 514-2200 / (800) 631-5245 / Fax: 609-514-2424 /usa.braccoimaging.com

Bracco Group